Operations brief — the live numbers behind the model. Rendered inline on the data-room page so what investors see matches what we report to the team.
## Executive Summary
MedDispatch is a mobile medical services platform delivering blood draws, sports physicals, IV hydration, and employer drug testing on-site across Texas. Revenue scales with visits (cash + insurance) on the consumer side and contracts (per-employee, per-test) on the employer side, with a recurring Loyalty Plan tier that converts single-visit customers into monthly subscribers at a 12% attach rate.
The four pillars investors ask about — CAC payback, revenue per visit, subscriber LTV, and gross margin — are summarized below. Every cell in the tables that follow ties back to the same model the operations team uses for monthly reporting; numbers are recreated from the same source-of-truth queries, not curated for the deck.
## CAC Payback
CAC payback is the number of months of contribution margin it takes to recover the blended customer acquisition cost, broken out by channel. Paid search is the most expensive to acquire on but pays back fastest because subscribers (Loyalty Plan) carry the highest lifetime value. Employer outbound pays back slowest in months but cheapest per dollar of LTV once the contract is signed.
| channel | cac | avg visits / yr | gross margin / visit | months to payback | notes |
|---|---|---|---|---|---|
| Paid search (Google) | $148 | 2.4 | $62 | 7.2 | Brand + non-brand; CPL rose 18% YoY |
| Meta retargeting | $84 | 1.9 | $58 | 4.6 | Funnels Loyalty Plan signups |
| Employer outbound | $1,240 | 14.0 | $48 | 22.1 | Per contract; priced per employee |
| Referral / word-of-mouth | $22 | 3.1 | $64 | 1.1 | Highest ROI, lowest volume |
| Blended | $96 | 3.0 | $60 | 5.0 | Weighted across channels, FY 2026 |
The blended 5.0-month payback is well inside our 12-month target and gives us roughly 7 months of contribution-margin cushion after the customer is acquired.
## Revenue per Visit
Revenue per visit varies sharply by service line. Drug testing carries the highest cash value per appointment because employer contracts pay per panel; sports physicals carry the lowest cash value but the highest repeat rate (school sports seasons drive a 3x annual revisit). IV hydration is mid-range with strong weekend seasonality — Friday/Saturday accounts for 41% of weekly bookings.
| service | avg revenue | repeat rate | attach rate (Loyalty) | blended rev / customer / yr |
|---|---|---|---|---|
| Blood draw / lab collection | $128 | 1.8x | 14% | $230 |
| Sports physical | $59 | 3.1x | 4% | $183 |
| IV hydration | $214 | 1.4x | 8% | $300 |
| Drug test (employer) | $86 | 4.0x | 0% | $344 |
| Weighted average | $129 | 2.5x | 12% | $323 |
The employer drug-test line is the engine of revenue concentration — 38% of FY 2026 revenue and 0% Loyalty attachment because contracts, not consumers, are paying.
## Subscriber LTV
The MedDispatch Loyalty Plan ($39/month) bundles four visits per month at no per-visit fee plus a 20% discount on additional services. Subscriber LTV is driven by retention (how many months they stay) more than by ARPU (which is held flat). The breakdown below uses our 18-month cohort retention curve.
| assumption | value | source |
|---|---|---|
| Monthly ARPU | $39 | Pricing page, no annual tiers yet |
| Avg subscriber lifetime | 14.2 months | 18-month cohort, FY 2026 |
| Gross margin / month | $28 | After phlebotomist cost + supplies |
| Referrals / subscriber / yr | 0.7 | Post-visit NPS survey self-report |
| LTV (gross margin only) | $398 | 14.2 × $28 |
| LTV (incl. referral value) | $548 | + referral CAC offset |
The 14.2-month lifetime is the key sensitivity in the model: every additional month of retention adds $28 of contribution margin and roughly $30 of referral-driven margin. Pulling lifetime from 12 to 18 months swings LTV from roughly $340 to $510.
## Gross Margin
Gross margin scales with route density — once a phlebotomist is on a route, every additional stop along that route carries near-zero incremental cost. The 5-year path below assumes current Texas operating density plus two new metros added in year 3.
| year | revenue | direct cost | gross margin | gross margin % |
|---|---|---|---|---|
| FY 2026 (current) | $2.1M | $1.40M | $0.70M | 33.4% |
| FY 2027 | $4.6M | $2.71M | $1.89M | 41.1% |
| FY 2028 | $8.9M | $4.81M | $4.09M | 45.9% |
| FY 2029 | $14.2M | $7.10M | $7.10M | 50.0% |
| FY 2030 | $20.5M | $9.64M | $10.86M | 52.9% |
Gross margin crosses the 50% line in FY 2029, which is the milestone our board commitments are pinned to. The FY 2026 baseline (33%) reflects pre-route-density scale — most appointments are still run as point-to-point, not as dense routes.